2026 AVBCC Agenda

REGISTRATION AND BREAKFAST

Early Riser Conversation 2
Lounge 9th Floor
REMOVING 340B’S PATIENT CLOAK OF INVISIBILITY – REFORMING THE PROGRAM TO PRIORITIZE PATIENTS
Moderator:
Kim Czubaruk, JD, VP of Policy, CancerCare
Faculty:
Robert Popovian, PharmD, MS, Founder, Conquest Advisors
Mesfin Tegenu, MS, RPh, CEO, RxParadigm

Early Riser Conversation 3
Presidents 10th Floor
ACCUMULATOR AND MAXIMIZERS: IMPACT TO ONCOLOGY DRUGS
Moderator:
Bryan Dennison, Sr. VP, Sales and Products, PaySign
Faculty:
Robert Estrada, Senior Director, Direct to Consumer – Oncology and Biopharma, AstraZeneca
Jayson Slotnik, JD, MPH, Partner, Health Policy Strategies

Early Riser Conversation 4
Olympic Suites 1 10th Floor
A WORKING PLAYBOOK FOR FUNDING CANCER INNOVATION
Moderator:
Ben Freeberg, Founder, Managing Partner, Oncology Ventures
Faculty:
Dan Caron, Founder & CEO, Health Universe
Kaitlin Christine, CEO & Founder, Gabbi

Opening comments and a review of the agenda.
Burt Zweigenhaft, PhD, Dlitt, Co-Founder, AVBCC

Key Opinion Leader Session 37
Lounge 9th Floor
OUTCOMES-BASED CONTRACTS IN ONCOLOGY: WHO OWNS THE OUTCOME?
We’ve been talking about outcomes-based contracts in oncology for years. In reality, most haven’t scaled and some haven’t lasted. Payers want real accountability on high-cost therapies, especially when benefit is still evolving at launch. Manufacturers want access, but push back on endpoints they don’t fully control. Providers are being asked to track and report outcomes without getting paid to do it. This session gets into what’s actually worked and what hasn’t. Where have these contracts held up? Where have they quietly fallen apart? What endpoints are people actually willing to stand behind? And is real-world data usable enough to support this and how can we evolve the model for a win-win-win position? Outcomes-based agreements (OBAs) are contracts where payment or compensation is tied to the successful achievement of specific, predefined results rather than for time spent or services rendered. This model shifts financial risk from the buyer to the provider, ensuring accountability and aligning incentives.
Moderator:
Cherry Moldovan, PhD, MSc, Director, US Access Strategy & Analytics, Precision AQ
Faculty:
Will Shrank, MD, Former CMO, Humana, Co-founder and CEO, Aradigm
Nancy Ruscio Bell, VP Head of Market Access, Celcuity
Michael Sherman, MD, MBA, MS, Principal, Sherman Healthcare Solutions; Former CMO, Harvard Pilgrim Health Care and Point32Health
Bruce Wilson, III, VP, US Oncology Care & Access, AstraZeneca
Kent Rogers, MBA, President, PBM, CarelonRx; Former Chief Industry Relations Officer, OptumRx

Key Opinion Leader Session 38
Presidents 10th Floor
COLLAPSING THE WALL BETWEEN RESEARCH AND ROUTINE CARE 
Why is “Research” still treated as a separate silo from “Care”? In the current oncology landscape, the artificial barrier between controlled clinical environments and the messy reality of a patient’s home remains a primary bottleneck for innovation. When every patient interaction is not captured as a structured data point, the ecosystem loses the invaluable “Real-World” experience that defines the true efficacy of a therapy. This session addresses the “Phase ¾ Cliff”—the phenomenon where drugs that perform exceptionally in pristine, small cohorts lose significant value due to unmanaged toxicities and poor adherence when introduced to the general population. The transition from a controlled trial to routine care is where value is either realized or lost. This session explores a radical convergence: embedding research-grade longitudinal data collection directly into the daily clinical workflow. By creating a “Living Laboratory,” providers can execute pragmatic trials at scale, identifying side effects in large cohorts—particularly those on complex oral therapies—far faster than traditional retrospective registries. The goal is to move from “studying” patients to creating a continuous feedback loop that informs care and regulatory evidence in real-time. 
Moderator:
Scott Howell, MD, Former US Chief Strategy Officer, Novartis; Co-founder, Impossible Medicine
Faculty:
John Fox, MD, MHA, Senior Medical Director for USCAN, Illumina
Jedd Wolchok, MD, PhD, FAACR, FAIO, FASCO, Meyer Director, Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine
Charles Ferte, MD, Chief Medical Officer, Resilience
Ahmed Sawas, MD, Medical Director, Flatiron
Enrique Velazquez Villarreal, MD, PhD, MPH, MS, Principal Investigator, City of Hope
Ezra Cohen, MD, CMO, Oncology, Tempus

Key Opinion Leader Session 39
Olympic Suite 1 10th Floor
ARTIFICIAL INTELLIGENCE AND THE IMPACT ON REVENUE CYCLE MANAGEMENT, BILLING, CODING, ANALYTICS, AND FINANCIAL OPERATIONS 
This panel will explore the impactful advantages that Artificial Intelligence can bring to revenue cycle management systems and financial performance overall to cancer system providers. 
Moderator:
Muna Tuna, US Market Pricing and Reimbursement Leader, Ernst & Young, LLP
Faculty:
Parag Shah, Chief Operating Officer, Integra Connect
Bobbi Buell, Principal, Provider Services & Reimbursement, OnPoint Oncology
Fiona Peoples, Vice President of Product, Unlimited Systems
Sarah Cevallos, VP Revenue Cycle and Payer Contracting, Navista
Ron DiGiaimo, MBA, FACHE, Chairman, R3/RCCS/RC Billing/Regents Health Resources/The Oncology Group

Key Opinion Leader Session 40
Olympic Suite 5 10th Floor
A LOOK IN THE MIRROR—WHY SELF-INSURED EMPLOYERS MUST RETHINK CANCER CARE MANAGEMENT 
Employers cover >70% of the commercial market as self-insured but are dissatisfied with the status quo as litigation and mistrust rise due to “self-dealing” and lack of transparency as cancer care is the top cost driver now affecting younger populations. This panel will discuss current state of cancer care and why legacy benefit designs and intermediaries (PBMs, brokers) are failing to deliver optimal outcomes. Key Questions will be answered such what is it that employers want for their employees regarding cancer care and where is the innovation and value-based approaches. Lastly what does that look like for employers? 
Moderator:
Heather Meade, JD, Principal, Washington Council, EY
Faculty:
Jenny Goins, Interim President & CEO, National Alliance of Healthcare Purchaser Coalitions
Christoph Dankert, Chief Network Officer, Carrum
Rebecca Warnken, Care Delivery Leader, Health Transformation, Aon
Sriya Srinath, Principal, Morgan Health Investments
Jenny Zaiser, VP of Provider Relations, Transcarent
Greg Green, Director of Business Development, MSK Direct, Memorial Sloan Kettering Cancer Center

Key Opinion Leader Session 41
Lounge 9th Floor
PHARMACEUTICAL INDUSTRY LEADERSHIP ORGANIZATIONS’ OUTLOOK
Industry leadership discusses the most impactful headwinds ahead for the cancer care ecosystem and patients.
Moderator:
Marci Mutti, MBA, EVP & Head of Consulting, ADVI Health
Faculty:
Susan Cantrell, RPh, MHL, CAE, CEO, AMCP
John O’Brien, PharmD, MPH, President & CEO, National Pharmaceutical Council
Greg Rotz, US Pharmaceuticals & Life Sciences (PLS) Advisory Leader, PwC
Maria Ghazal, President & CEO, Healthcare Leadership Council
Joe Franklin, JD, PhD, Chief Legal & Policy Officer, BIO

Key Opinion Leader Session 42
Presidents 10th Floor
THE SUPPLY CHANNEL: CONTRACTING IN THE BRAVE NEW WORLD OF TRANSPARENCY
Oncology’s supply channel is being asked to deliver far more than a price. This panel brings together leaders across the value chain to examine three shifts redefining the space: how distributor-provider relationships have moved from transactional to value-based partnerships as IRA and Most Favored Nation pricing add new layers of risk; how proposed 340B reimbursement cuts could push hospital-employed oncologists into community practice, and whether that setting can absorb them; and why MSOs, once viewed with skepticism, have become central to how practices manage complexity and prove their value to manufacturers.
Moderator:
Jeff Lovesy, SVP & GM Commercial Partnerships, Thyme Care
Faculty:
Tesh Khullar, MBA, Founder & CEO, Prism TPO
Michael French, VP, Manufacturer Business Development, Oncology GPOs, McKesson
Ginger Ertel, MBA, SVP, Pharmacy Member Services, Vizient
Srin Vishwanath, CEO, OPN Healthcare
Stephanie Mayfield, PharmD, Senior Director, Specialty Programs, Cardinal Health
Rick Lozano, SVP, GPO Operations & Manufacturer Relations, Cencora

Key Opinion Leader Session 43
Olympic Suite 1 10th Floor
THE $2-3 MILLION INFUSION: WILL CELL AND GENE THERAPY BREAK THE PAYER MODEL?
With CAR-T and gene therapies exceeding the lifetime value of a commercial member, the math is broken or not? Although the science is extremely compelling in the clinical studies in the real world the replication is not happening. The panel will examine several issues; one the lack of coverage and standardized process to approve a patient’s therapy and the lack of consistent and fair reimbursement. The panel will also examine alternates such as “carve-outs,” outcomes-based contracting, and how disruptors are reshaping the marketplace for high-cost therapies. 
Moderator:
Alicia Silver, MPP, Head of Cell and Gene Therapy Market Access, ADVI Health
Faculty:
Spencer Carrucciu, Co-founder, Aradigm
Fran Gregory, PharmD, MBA, VP, Emerging Therapies, Cardinal Health
Joe DePinto, Head of Cell, Gene and Advanced Therapies, McKesson
Daniel Goldstein, MD, Director, Center for Health Economics, The Davidoff Center, Rabin Medical Center, Israel
Phung Osborn, VP, Global Market Access, Cell Therapy, BMS
Sibel Blau, MD, President & CEO, ONCare Alliance/Exigent Research

Key Opinion Leader Session 44
Olympic Suite 5 10th Floor
ARTIFICIAL INTELLIGENCE AND IMPACT ON SPECIALTY MEDICALLY INTEGRATED PHARMACY
This panel will dig into the considerations and improvements in access, contacting, impacting care and outcomes that the incorporation of Artificial intelligence in specialty pharmacy will have in terms of outcomes and costs. 
Moderator:
Jorge J. Garcia, PharmD, MS, MHA, MBA, Founder & Principal, Patagonia Healthcare
Faculty:
Connie Sullivan, President & CEO, National Home Infusion Association
Ela Lourido, VP/GM Specialty Pharmacy Solutions, Biologics by McKesson
James Gilmore, PharmD, Chief Pharmacy and Clinical Services Officer, AON
Stephen Ziter, MBA, Chief Operating Officer, NCODA
Wafa Samara, PharmD, VP & Chief Pharmacy Officer, City of Hope
Jeff Lombardo, PharmD, MBA, BCOP, Vice President, Enterprise Clinical Services, Onco360

Key Opinion Leader Session 45
Lounge 9th Floor
WHO OWNS CANCER CARE? THE NEW POWER MAP OF ONCOLOGY
Distributors, health systems, PE-backed platforms, physician employers, and integrated delivery networks are reshaping oncology’s business landscape. How are evolving ownership structures changing incentives, access, and the future role of independent practices?
Moderator:
Maddi Davidson, Managing Director of Market Access, Avalere Health
Faculty:
Lauren Makhoul, Director, M&A Advisory, Manatt Health
Todd Schonherz, CEO, AON
Jeff Hunnicutt, Chief Operating Officer, Navista
Harlan Levine, MD, President, Health Innovation and Policy, City of Hope
Lisa Smith, RPh, SVP and President, Specialty Distribution and Solutions, Cencora

Key Opinion Leader Session 46
Presidents 10th Floor
THE MRD DELUSION: IS HIGH-COST SURVEILLANCE IMPROVING OUTCOMES OR JUST ESCALATING SPEND? 
MRD testing is the new frontier for solid tumors, but managed care is skeptical. Is this the “holy grail” for therapy de-escalation, or a multibillion-dollar “anxiety tax”? This panel debates whether clinical utility justifies the managed care spend. 
Moderator:
John Fox, MD, MHA, Senior Medical Director for USCAN, Illumina
Faculty:
Lucy Langer, MS, MD, National Medical Director, Oncology and Genomics, UnitedHealthcare
Julie Wiedower, PhD, CGC, Senior Director, Medical Affairs, Managed Care, Guardant Health
Lorraine Brisbin, MS, MLS, Sr. VP, Precision Medicine, Texas Oncology
TJ Slavin, MD, MBA, Chief Medical Officer, Diagnostics, Tempus AI
Yuri Fesko, MD, Chief Medical Officer, Quanterix
Peter Bryant-Greenwood, MD, MBA, Medical Director, Corgenix Clinical Laboratory, Sebia
Daniel Edelstein, MBA, MS, General Manager, Quest Diagnostics

Key Opinion Leader Session 47
Olympic Suite 1 10th Floor
THE IRREPLACEABLE PARTNERSHIP: HUMAN AND AI IN HEALTHCARE
Practical approaches to integrating emotional intelligence, creativity, contextual judgment, institutional knowledge, and physical agency to unlock AI’s full potential.
Healthcare depends on capabilities no technology can fully replicate: emotional intelligence, creativity, contextual judgment, institutional knowledge, and physical agency. These qualities are not peripheral to healthcare economics; they shape how organizations solve problems, design workflows, and manage patient access, provider operations, and revenue cycle performance. As AI advances, the central challenge is not simply where to deploy it, but how to build the foundation for effective partnership between humans and AI.
This panel examines the practical steps organizations are taking to build a foundational AI strategy: how to identify the right starting point, structure early human-AI partnership models, strengthen solution development with AI rather than simply delegate work to it, assess and strengthen the security posture required to support AI adoption, and embed healthcare data privacy and security from the start.
Moderator:
Joe Baffone, Strategic Advisor & Healthcare Venture Builder
Faculty:
Brad Frazier, Co-Founder & CEO, Annexus Health
Lavi Kwiatkowsky, CEO & Founder, Canopy
Alex Lukashevich, Chief AI Officer, Forte Group
Davey Daniel, MD, Chief Medical Officer, OneOncology
Ryan Hampton, MS, VP, Industry Relations and Implementation, Biologics by McKesson
Melissa Weirich, Senior Director, Access and Precision Medicine, AstraZeneca

Key Opinion Leader Session 48
Olympic Suite 5 10th Floor
FINANCING CAR-T & GENE THERAPY: INPATIENT VERSUS OUTPATIENT REALITIES
CAR-T is the hottest topic in cancer, but no one is covering their actual costs on this innovative therapy because it is very labor intensive for the physicians and institutions alike. The academic institutions have no idea what the finances of a CAR-T patient means for their bottom line and the payers are terrified of per patient costs that run from $2-5 million. Providers and CAR-T manufacturers are interested in reaching more patients closer to home. More than a year since REM requirements were removed for CAR-T and nearly one year since FACT Community Standards were released, have we seen meaningful movement? This panel will surface the market realities and offer up scalable solutions so healthcare markets can address patient demand responsibility.
Ending in a discussion on what is left to do and what roadblocks need to be addressed to facilitate access?
Moderator:
Kolton Gustafson, MPH, Managing Director, Avalere Health
Faculty:
Tara Graff, DO, MS, Director of Clinical Trials, Mission Cancer + Blood/UIHSMG; Director of Cellular Therapy, Exigent Research
John Powderly, MD, Founder & President, Carolina BioOncology Institute, BioCytics Human Applications Lab
Barry Brooks, MD, MBA, Medical Director of GPO Services, McKesson Specialty Health
Laura Okpala, MPH, Executive Director, US Reimbursement Policy, Gilead
Aaron Lyss, MBA, Senior Director, Payment and Policy Innovation, OneOncology

Key Opinion Leader Session 49
Lounge 9th Floor
HOW WILL PHARMACEUTICALS BE EVALUATED ON VALUE IN THE TRANSPARENCY WORLD
As price transparency requirements strip away the list price fiction (hospital price transparency, state drug pricing transparency laws requiring WAC increase reporting, PBM rebate disclosure), the negotiating leverage that used to hide behind opaque rebates and net pricing starts to erode. Payers, employers, and increasingly patients can see the gap between list and net, which shifts the burden of justification from “what does it cost” to “what does it do.” The open question is whether manufacturers get ahead of this by generating their own real-world evidence and outcomes data proactively, or whether third-party assessors (ICER, payers’ own P&T committees, eventually CMS under IRA-adjacent authorities) fill that vacuum and set the terms unilaterally. Once the pricing becomes visible, the value story has to hold up on its own; there’s no rebate structure left to paper over a weak evidence base.
Moderator:
Jayson Slotnik, JD, MPH, Partner, Health Policy Strategies
Faculty:
Antonio Ciaccia, CEO, 46Brooklyn Research
John O’Brien, PharmD, MPH, President & CEO, National Pharmaceutical Council
Jenny Goins, Interim President & CEO, National Alliance of Healthcare Purchaser Coalitions
Robert Popovian, PharmD, MS, Founder, Conquest Advisors
Jeff Davis, Executive Director National Channel, AstraZeneca

Key Opinion Leader Session 50
Presidents 10th Floor
MSOs AND VALUE-BASED CANCER CARE: ARE WE FINALLY BUILDING THE INFRASTRUCTURE PATIENTS NEED? 
As oncology care shifts toward valuebased models, Management Services Organizations (MSOs) are increasingly positioned as the operational backbone for community practices. This session will examine whether MSOs are truly building the infrastructure needed to improve patient access, coordination, and outcomes—or if gaps remain between scale, valuebased ambition, and the realities of delivering care in the community setting. 
Moderator:
Gary Herschman, Esq, Shareholder, Co-Chair, Health Care Transactions Group, Baker Donelson
Faculty:
Diana Verrilli, General Manager, Navista
Todd Schonherz, CEO, AON
Robert Baird, RN, MSA, President, National Cancer Treatment Alliance
Adria Warren, JD, Partner, Foley & Laudner
Casey Rhode, Chief Strategy Officer, OneOncology
Rhonda Henschel, MBA, SVP, Payer Lifecycle and Value Optimization, McKesson
Dana Jacoby, MS, Founder & CEO, Vector Medical Group

Key Opinion Leader Session 51
Olympic Suite 1 10th Floor
REMOTE THERAPEUTIC MONITORING: HOW REAL-TIME MONITORING OF CANCER PATIENTS AT SCALE CAN IMPROVE OUTCOMES 
Remote therapeutic monitoring allows practices to monitor large numbers of patients in real time for important clinical symptoms related to disease activity or treatment toxicity. Although CPT codes exist for pulmonary, musculoskeletal, and behavioral health conditions, a code does not specifically exist for cancer. This panel will discuss the rationale for remote therapeutic monitoring, how current codes apply to cancer patients, and how a cancer-specific code would improve the care of cancer patients. 
Moderator:
Ethan Basch, MD, MSc, Director, Cancer Outcomes Research Program; Professor, Medicine and Public Health, UNC-Chapel Hill
Faculty:
Gury Doshi, MD, Medical Director, Texas Oncology
Lekan Ajayi, PharmD, MBA, FACCC, COO, Highlands Oncology
Brian Bourbeau, MA, MBA, Vice President, Care Delivery, ASCO
Gabrielle Rocque, MD, MS, Chief Medical Officer, Atlas Oncology Partners; Associate Professor, University of Alabama at Birmingham
Misha Kaur, Chief Operating Officer, Cureety
Nicole Chambers, EVP, Commercial GPO & Oncology Development, PatientPoint

Key Opinion Leader Session 52
Olympic Suite 5 10th Floor
WALL STREET AND THE CANCER CARE ECOSYSTEM: NAVIGATING POLICY AND MARKET HEADWINDS
Join moderator Ipsita Smolinski (Capitol Street) and top financial analysts Geoff Meacham (Citigroup), Lisa Gill (JPMorgan), and Tycho Peterson (Jeffries) for an in-depth discussion on the intersection of capital markets and the evolving cancer care landscape. This panel will move beyond the aspirations of Value-Based Care to assess the real-world headwinds currently facing providers and investors. Key discussion topics will include the impact of supply chain verticalization, PBM and 340B reforms, and the influence of CMS initiatives (CRUSH) on molecular diagnostic testing and oncology manufacturing. We will navigate the increasingly complex policy backdrop — tariffs, MFN and IRA drug negotiation — offering Wall Street perspectives on current paradigms and future challenges.
Moderator:
Ipsita Smolinski, MPH, MBA, Founder & Managing Director, Capitol Street
Faculty:
Lisa Gill, Managing Director, JP Morgan
Geoff Meacham, PhD, Managing Director, Citi
Tycho Peterson, MSc, MBA, Managing Director, Global Equities, Jefferies
David Khtikian, MBA, Co-Founder & Partner, Mainstay Healthcare Partners; Former PM, Wellington Management

Lunch

Use Case 3
Lounge 9th Floor
340B PRE-ADJUDICATION: TRANSFORMING DRUG PRICING THROUGH PROSPECTIVE CLAIM MANAGEMENT: PAYER AND PROVIDER PERSPECTIVE
AS the 340B landscape evolves toward rebate-based administration, covered entities , manufacturers and payers face mounting challenges involving upfront drug acquisition costs, duplicate discounts, fragmented claim data, dispute resolution and retrospective reconciliation.
This session explores 340B claim pre-adjudication as a viable alternative to traditional administration models—enabling earlier eligibility verification, persistent claim identification, dispute resolution and coordinated financial transactions across the pharmaceutical supply chain.
Key discussion points
Rethinking the 340B financial model: Examine how verified claims and coordinated purchasing could reduce or eliminate upfront Wholesale Acquisition Cost (WAC) exposure for covered entities.
Establishing a single source of truth: Explore how point-of-sale verification and persistent 340B claim identifiers can strengthen transparency, prevent duplicate discounts, and improve manufacturer visibility.
Connecting claims to purchasing and payment: Evaluate opportunities to integrate eligibility determination, wholesaler transactions, rebate administration, reconciliation, and dispute resolution.
Addressing stakeholder concerns: Examine providers concerns on the potential for payer-based discriminatory pricing, data privacy risks, and the safeguards necessary to protect covered entities and patients.
Moving from concept to implementation: Demonstrate how existing technology can support prospective, transaction-level administration and identify the operational and policy barriers to broader adoption.
Key takeaway: An examination of whether prospective 340B claim management can reconcile covered entities’ financial needs with manufacturers’ requirements for transaction integrity, compliance, and accountability while also taking into considerations PBMs/payer’s needs.
Moderator:Mesfin Tegenu, MS, RPh, CEO, RxParadigm
Faculty:
Steve Cutts, PharmD, SVP, Chief Clinical and Specialty Officer, Prime Therapeutics
Katy Felice Lees, MSBA, 340B ACE, Director, 340B Policy and Business Strategy, University of Rochester, Medicine
Laure Reiss, Chief Strategy Officer, RxParadigm

Lunch and Learn 3
Lounge 9th Floor
HOW INNOVATIVE LEADERSHIP CAN RESHAPE AN INDUSTRY
John Oyler, MBA, CEO, BeOne Medicines reflects on what leadership can do to transform and improve innovation in cancer care.
Moderator:
Michael Kolodziej, MD, CMO, Canopy
Faculty:
John Oyler, MBA, Co-founder, Chairman & CEO, BeOne Medicine

Use Case 4
Presidents 10th Floor
USE CASES IN VALUE-BASED CARE CONTRACTS: CAREOLOGY HEALTH
Value-based care contracts, after years of discussion, are finally beginning gain traction. Several use cases will be discussed by the partners that developed an innovative approach to contracting.
Moderator:
Jon Zimmerman, Co-Chair, AVBCC Regional Collaboratives
Faculty:
Andrew Blackmon, SVP, Strategic Growth, Careology Health

Use Case 5
Presidents 10th Floor
USE CASES IN VALUE-BASED CARE CONTRACTS: AON & EVOLENT
Value-based care contracts, after years of discussion, are finally beginning gain traction. Several use cases will be discussed by the partners that developed an innovative approach to contracting.
Moderator:
Jon Zimmerman, Co-Chair, AVBCC Regional Collaboratives
Faculty:
Alti Rahman, MHA, MBA, CSSBB, Chief Strategy & Innovation Officer, AON
Evolent

Lunch and Learn 2
Presidents 10th Floor
PREPARE, REACT, OR BOTH? MARKET IMPLICATIONS AT THE INTERSECTION OF PATENT EXPIRY AND PRICE REFORM
As the PD-1 class faces a historic inflection point — with loss of exclusivity arriving in 2028 and Most Favored Nation pricing following close behind — manufacturers, payers, and providers are navigating a compounding set of pressures unlike anything oncology has seen before. This discussion will explore how key stakeholders are preparing, what scenarios are most likely to unfold, and what the downstream consequences mean for the broader market: LOE & MFN: By the numbers, when and how will LOE and MFP be introduced, and how will that compare to current state? Implications: What potential future scenarios exist, and how are manufacturers, payers, and providers preparing today? Near- and Long-Term: What is the likely impact / second-order effects on innovation, and how can stakeholders collaborate to support sustainability?
Moderator:
Aaron McKeon-Fish, Managing Partner, Dedham Group
Faculty:
Barbara McAneny, MD, Past President, American Medical Association; Co-Chair, ONCare Alliance; CEO, New Mexico Oncology Hematology Consultants
Bryce Platt, PharmD, Director, Drug Channel Institute
Antonio Ciaccia, CEO, 46Brooklyn Research

Key Opinion Leader Session 53
Lounge 9th Floor
PBM, GPO, AND WHOLESALER CONTRACTING: HAS GOVERNMENT LITIGATION AND SETTLEMENTS CHANGED THE MODEL?
Government litigation and settlements involving PBMs, GPOs, and wholesalers, scrutinize PBM vertical integration. Simultaneously, DOJ settlements over generic drug pricing and distribution practices, have put long-standing contracting norms under a spotlight they had not faced before. This panel examines whether that scrutiny has actually altered how these intermediaries structure rebate guarantees, formulary placement terms, GPO fees, and wholesaler chargeback arrangements, or whether the core economics have simply adapted around new disclosure requirements while leaving the underlying incentive structures intact. Panelists will discuss what manufacturers, health systems, and payers should expect going forward: are we seeing genuine renegotiation of the value chain, or a more sophisticated version of the same model built to withstand the next round of enforcement.
Moderator:
Jayson Slotnik, MPH, JD, Partner, Health Policy Strategies
Faculty:
Elizabeth Anderson, MBA, Senior Managing Director, Evercore ISI
Jonathan Levitt, Esq., Co-Managing Partner, Frier Levitt
Tim Dube, MPH, SVP, Policy and Regulatory Insights, PCMA
Barry Fortner, PhD, MS, Founder & Managing Partner, Realmedica Strategies, LLC
Jon Hamrick, MBA, Partner, Curatio Advisors
Steve Cutts, PharmD, SVP, Chief Clinical and Specialty Officer, Prime Therapeutics

Key Opinion Leader Session 54
Presidents 10th Floor
IF YOU’RE WORRIED ABOUT THE IRA IMPACT, CHECK YOUR REAR-VIEW MIRROR
CMS changes to price reporting: transparency consequences impacting ASP, MFN, IRA, 340B, and bona fide fair market value service fee requirements. Adding new submission obligations to manufacturers.  How did this impact the channel? Have the relationships between manufacturers, distributors and downstream purchasers changed? How should all the stakeholders prepare for the intended and unintended consequences of this change.
Moderator:
Jeff Berkowitz, JD, CEO, Real Endpoints
Faculty:
Margaux Hall, JD, Partner, Gibson Dunn
Jennifer Snow, Founder, Apteka
Muna Tuna, US Market Pricing and Reimbursement Leader, Ernst & Young, LLP
Greg Pugh, JD, Executive Director, Value & Access, CMS, Boehringer Ingelheim

Key Opinion Leader Session 55
Olympic Suite 1 10th Floor
THE NEW PARADIGM—DIGITALLY ENABLED, GENOMICS-FIRST, VALUE-BASED CANCER CARE 
As targeted therapies proliferate, biomarker testing remains unevenly implemented across care settings. Begin care with CGP at diagnosis; use AI for treatment planning and clinical trial matching. Digital tools enable remote monitoring, real-time decision support, and proactive interventions. Value-based care models require comprehensive, longitudinal data and aligned incentives. Panelists discuss implementation strategies, change management, patient centric care across the care journey, and the future of employer-driven cancer care innovation. Stakeholders will discuss coverage policy, operational barriers, state legislation, and strategies to ensure patients receive appropriate testing when it matters most.
Moderator:
Laura Housman, DrPH, MBA, MPH, Chief Public Health Officer, Avalere
Faculty:
Ira Klein, MD, Vice President, Medical Affairs and Payer Relations, Tempus AI
James Hamrick, MD, MPH, SVP, Chair, Caris Precision Oncology Alliance, Caris Life Sciences
Lucy Langer, MS, MD, National Medical Director, Oncology and Genomics, UnitedHealthcare
Stacey Gilbert, MPH, MBA, Director, Precision Medicine, ADVI Health
Jodi Bass, Vice President, VP, Global Commercial Precision Medicine, Johnson & Johnson
Toby Basey-Fisher, PhD, CEO & Founder, Entia

Key Opinion Leader Session 56
Olympic Suite 5 10th Floor
MARKET DEFLATION OR FAILURE? THE FUTURE OF BIOSIMILARS IN ONCOLOGY 
Biosimilars were expected to deliver sustainable savings and long-term competition but accelerating price deflation and shifting ASP dynamics are raising questions about the market’s future. This panel will explore whether current ASP trends are driving efficiency—or undermining incentives for manufacturers, providers, and continued biosimilar investment. Panelists will examine what market deflation means for access, competition, and the long-term role of biosimilars in value-based cancer care.
Moderator:
Barry Brooks, MD, MBA, Medical Director of GPO Services, McKesson Specialty Health
Faculty:
Natalie Bedford, SVP, US Pharmaceutical Distribution Services, McKesson
David Senior, MPH, President & SVP, Strategic Global Sourcing and Policy Economics, Cencora
Edward Li, MPH, PharmD, Head, HEOR and Oncology, Sandoz
Sean McGowan, MBA, VP, Biosimilars & Branded Oncology, Amneal
Philip Sclafani, Partner, PwC
Tyler Novotny, SVP, Drug Channels Institute

Key Opinion Leader Session 57
Lounge 9th Floor
INSURANCE INDUSTRY: A FORWARD OUTLOOK
Commercial health insurance is a vital component of the cancer care ecosystem. In this panel we will review with health plan physician leaders the current state of affairs in commercial health plan oncology programs. Topics will include utilization management, care delivery networks and site of service, alternative payment models, and identifying and paying for quality.
Moderator:
Michael Kolodziej, MD, CMO, Canopy
Faculty:
Gerry Stanley, MD, P-CEO, Former CMO, Express Scripts EverNorth
Bryan Loy, MD, MBA, Consultant and former Corporate Medical Director
Lucy Langer, MS, MD, National Medical Director, Oncology and Genomics, UnitedHealthcare
Matthew T. Smith, MD, MMM, MS, CPE, Sr. Executive Medical Director, Medical Appeals and Pharmacy Solutions, Health Care Service Corporation, Blue Cross and Blue Shield of Illinois, Montana, New Mexico, Oklahoma & Texas
Michael Sherman, MD, MBA, MS, Principal, Sherman Healthcare Solutions; Former CMO, Harvard Pilgrim Health Care and Point32Health

Key Opinion Leader Session 58
Presidents 10th Floor
MFP OR 340B: LESSONS LEARNED FROM IPAY 2026, WHAT’S NEXT FOR IPAY 2027 
Discussion the latest data and experience with how IPAY 2026 functioned, including lessons learned, stakeholder challenges, and opportunities. This information is critical as additional oncology products are swept into CMS MFP negotiation. Learn how the process has evolved and will evolve for IPAY 2027. Discuss unintended consequences, including Part D 340B carve-outs and the decline of 340B contract pharmacy. 
Moderator:
Ethan Dubin, MPH, Product & Strategy Lead, Second Sight Solutions
Faculty:
Jennifer Lospinoso, President, Riparian
Lisa Schwartz, PharmD, RPh, Sr. Director, Professional Affairs, National Community Pharmacists Association
Rory Martin, PhD, Senior Principal, Market Access Technology Solutions, IQVIA
Katie Holcomb, FSA, MAAA, Principal and Consulting Actuary, Milliman
William Newton, Editor in Chief, 340B Report
Peter Avalos, MBA, MS, VP Market Access and Pricing, Summit Therapeutics

Key Opinion Leader Session 59
Olympic Suite 1 10th Floor
BEYOND MONITORING: USING LONGITUDINAL PATIENT DATA TO ANTICIPATE AND ORCHESTRATE CARE 
Oncology monitoring today is fundamentally reactive. A patient reports a symptom. A nurse responds. Even the best-implemented ePRO platforms are built around this loop: capture the signal, escalate the alert, manage the episode. This session proposes a different question entirely: which patients three weeks from now is most likely to experience a treatment-limiting toxicity, an unplanned admission, or a dose reduction; what do I do about it today, before the deterioration event occurs? This shift from surveillance to foresight changes not just how clinicians respond to patients, but when and how they structure care decisions across an entire patient population.  This session is an honest account of where the science stands, what prospective validation requires, and an open invitation to the community oncology leaders in the room to become part of it. 
Moderator:
Douglas Flora, MD, LSSBB, President-Elect, ACCC; Executive Medical Director, Oncology Services, Yung Family Cancer Center, St. Elizabeth Healthcare; CEO, TensorBlack
Faculty:
Ethan Basch, MD, MSc, Director, Cancer Outcomes Research Program; Professor, Medicine and Public Health, UNC-Chapel Hill
Samyukta Mullangi, MD, MBA, VP, Clinical Strategy, OpenEvidence
Lavi Kwiatkowsky, CEO & Founder, Canopy
Stan Kachnowski, PhD, Director, Columbia University Business School, Digital Health Technology
Carole Tremonti, RN, MBA, VP, CancerLinQ & Provider Partnerships, Concert AI
Charles Ferte, MD, Chief Medical Officer, Resilience
Angela Taber, MD, Medical Director, Daymark Health

Key Opinion Leader Session 60
Olympic Suite 5 10th Floor
OBESITY, GLP-1s AND CANCER PREVENTION: ARE WE WITNESSING THE NEXT REVOLUTION IN ONCOLOGY?
GLP-1 therapies are transforming obesity management, but their potential impact on cancer prevention may be even more significant. Emerging evidence suggests meaningful reductions in obesity-associated cancers, yet important scientific questions remain. Are observed benefits driven solely by weight loss, or do GLP-1 therapies exert independent biologic effects? As employers redesign benefits, Medicare launches new demonstrations, and manufacturers pursue additional evidence, oncology stakeholders must begin preparing for how obesity treatment could fundamentally alter cancer incidence, screening strategies, payer policy, and long-term healthcare spending.
Moderator:
Cheryl Ann Allen, BS Pharm, MBA, Partner, Curatio Advisors
Faculty:
Ryan Juhring, PharmD, MBA, Pharmaceutical Manufacturer Relations Executive (DTC/DTE programs), CenterWell
Whitney Amyot, PhD, Managing Director, EY
Daishia Hord, MS, RVP, Sales, HealthDyne

Key Opinion Leader Session 61
Lounge 9th Floor
ELITE TECHNOLOGY FINALLY COMES TO RESCUE HEALTHCARE
Seema is the Executive Vice President and general manager of Oracle Health and Life Sciences, where she’s responsible for Oracle’s clinical and clinical trials applications portfolio. Seema has more than 25 years of experience leading transformative initiatives across the healthcare industry. In her current role, she’s spearheading the development of Oracle’s next-generation electronic health record system, transforming it into a clinical asset to help improve care delivery. She’s also focused on closing the gap between clinical research and clinical care to help improve patient outcomes. Seema was the administrator of the Centers for Medicare & Medicaid Services (CMS) from 2017 to 2021. In this role, she developed and implemented the federal administration’s healthcare plan to advance value-based care, innovation, interoperability, and price transparency while reducing drug prices and regulations through her historic Patients over Paperwork initiative.
Prior to her role at CMS, Seema founded and sold a national health policy consulting company and worked as a vice president for policy and planning for a public hospital, public health department, and health system. These experiences provided her with invaluable insight into the challenges healthcare professionals face on the front lines of the industry.
She currently serves on the boards of Eskanazi Health Foundation, the Association of Clinical Research Organizations, and USC’s Schaeffer Center for Health Policy & Economics. She holds degrees from the University of Maryland and Johns Hopkins University School of Public Health.
Moderator:
John O’Brien, PharmD, MPH, President & Chief Executive Officer, National Pharmaceutical Council
Faculty:
Seema Verma, Executive Vice President and General Manager, Oracle Health and Life Sciences

Key Opinion Leader Session 62
Presidents 10th Floor
MIDDLEMEN, DRUG AGGREGATORS, GROUP PURCHASING ORGANIZATIONS: MARKET RELEVANCE ON VALUE AS TRANSPARENCY TAKES HOLD
Just maybe all middlemen are not middlemen. Pricing and reimbursement pressures have created an economic environment where end users and producers have started to question the cost of middlemen in-between the contractual relationship. Historically GPO’s and Buying groups have provided recognizable value and benefit; but some activities and value today are questioned by the marketplace. Understanding that ecosystems and business models evolve this panel will tackle the issues of today and forecast what the GPO’s and Buying Groups of the future will become. They also will answer to the critics call out on value delivered or not.
Moderator:
Jeff Becker, SVP and Managing Director, Precision AQ
Faculty:
Azra Behlim, PharmD, MBA, AVP, Pharmacy & Services, Vizient
Stephanie Mayfield, PharmD, Senior Director, Specialty Programs, Cardinal Health
Chris O’Dell, President, Turquoise
Rick Lozano, SVP, GPO Operations & Manufacturer Relations, Cencora
Tim Ward, JD, Founder, President & Chief Legal Officer, Hercules

Key Opinion Leader Session 63
Olympic Suite 1 10th Floor
EMERGING PBM TRANSPARENCY MODELS
The markets are calling for pass through transparency. As answers to these calls, innovative PBM models are appearing to respond. This panel of innovative thought leaders will discuss the solution to the unsustainable big three PBM models that dominate the industry today.
Moderator:
Adam Colborn, JD, VP, Government Affairs, AMCP
Faculty:
Carl Bertram, President, ClearScript
Kristin Begley, PharmD, Chief Commercial Officer, Judi Health
Ryan Foster, PharmD, MBA, VP, Value Delivery, AffirmedRx
Gerry Stanley, MD, P-CEO, Former CMO, Express Scripts EverNorth
Steve Cutts, PharmD, SVP, Chief Clinical and Specialty Officer, Prime Therapeutics

Key Opinion Leader Session 64
Olympic Suite 5 10th Floor
THE FINE PRINT IN CANCER CARE: STEP EDITS, PA, UM, STANDARDS, AND MEDICALLY INTEGRATED CANCER CARE
As medically integrated practices (MIPs) continue to evolve within an increasingly complex healthcare landscape, alignment across policy, payers, and care delivery is more critical than ever. This session will examine the growing impact of step edit protocols and accreditation requirements on medically integrated oncology and specialty care models. Panelists will explore how these forces influence patient access, operational workflows, and strategic positioning within health systems and payer networks. 
Moderator:
Jonas Congelli, Associate Executive Director, NCODA
Faculty:
Scott Freeswick, MS, PharmD, Vice President/Chief Pharmacy Officer, Memorial Sloan Kettering
Austin Cox, PharmD, VP, Pharmacy Services, Florida Cancer Specialists & Research Institute
Brian Morrissey, MBA, Vice President, Oncology Accounts Group, Pfizer

Key Opinion Leader Session 65
Lounge 9th Floor
NEW ECONOMICS NEW MODELS FOR THE CANCER CARE PROVIDERS ECOSYSTEM
Issues covered from loss of drug reimbursements, bundles in care, capitation, risk models, and value-based care.
Moderator:
Michael Kolodziej, MD, CMO, Canopy
Faculty:
Jeffrey Scott, MD, President & Chief Medical Officer, Integra Connect
Yale Podnos, MD, MPH, FACS, CMO, Starling Oncology
Rhonda Henschel, MBA, SVP, Payer Lifecycle and Value Optimization, McKesson
Ed Licitra, MD, PhD, CEO, Astera Health Partners/Astera Cancer Care; Founder, Vantris Health
Nick Lefeber, MBA, Total Cost of Care, Value-Based Care, Medical Economics, BCBS Rhode Island
Mike Fazio, Head of Value-Based Care, Navista

Key Opinion Leader Session 66
Presidents 10th Floor
TRENDS IN CANCER CARE
The Cancer Care Ecosystem has been in monumental transition primely driven by aggressive executive orders, public policy, legislative initiatives, Industry consolidation, deepening middlemen rent seeking utilities pressures, emerging new drug and CGT technologies and of course Artificial Intelligence. In this session the key impact of the above will be weighed against the real-world data, metrics, and insights key industry observational experts have to help us better understand what has changed with a keen eye at expressing what the forecast ahead might be.
Moderator:
William McGivney, PhD, Managing Partner, McGivney Global Advisors
Faculty:
Bruce Pyenson, FSA, MAAA, Principal, Pyenson Healthcare Analytics
Peter Wright, Partner, McKinsey & Company
Murray Aitken, MBA, Executive Director, IQVIA Institute for Human Data Science and Visiting Professor in Practice, The London School of Economics and Political Science

Key Opinion Leader Session 67
Olympic Suite 1 10th Floor
WHO ACTUALLY PAYS WHEN THE ONCOLOGIST PRESCRIBES THE DRUG?
The fundamental tension in oncology value-based care remains unresolved: the clinician making a six-figure treatment decision often operates within a reimbursement model that directly benefits from higher drug spend. While the Enhancing Oncology Model (EOM) and other risk arrangements have created new accountability structures, they have not fully realigned incentives at the point of prescribing. As biosimilar adoption, site-of-care optimization, and dosing reform become increasingly important cost-management levers, the industry must confront the question of who truly bears financial responsibility for drug utilization.The discussion can examine whether current payment models are capable of delivering sustainable oncology affordability without changing prescribing incentives.
Moderator:
Lekan Ajayi, PharmD, MBA, FACCC, COO, Highlands Oncology
Faculty:
Bobby Green, MD, Co-Founder, President & CMO, Thyme Care
Daniel Goldstein, MD, Director, Center for Health Economics, The Davidoff Center, Rabin Medical Center, Israel
Jordan McInerney, Chief Development Officer, Starling Oncology
Stephen Schleicher, MD, MBA, FASCO, Medical Oncologist, Tennessee Oncology

Key Opinion Leader Session 68
Olympic Suite 5 10th Floor
GERIATRIC ONCOLOGY IS THE NEXT MAJOR VALUE-BASED CARE OPPORTUNITY
Chronologic age is a poor predictor of treatment tolerance. Functional status, cognition, and polypharmacy often matter more. Yet these factors remain inconsistently incorporated into treatment decisions. As the oncology population ages, risk-bearing organizations have an opportunity to operationalize geriatric assessment at scale and develop clinical models aligned to the specific needs of this population.
This session will look at the measurable implications of unaddressed geriatric oncology needs, specifically on toxicity, hospitalization, treatment adherence, and total cost of care.
Moderator:
Lalan Wilfong, MD, CMO, Navista
Faculty:
Bryan Loy, MD, MBA, Consultant and former Corporate Medical Director
Julia Frydman, MD, MS, VP Clinical Outcomes & Quality, Thyme Care
Ramy Sedhom, MD, FASCO, Director for the Center for Cancer and Aging at Penn Medicine
David Johnson, MD, MPH, Co-Founder and Chief Physician Executive, Atlas Oncology Partners
Dana Carne, MD, MBA, Chief Medical Office for High-Value Care, Aetna

Key Opinion Leader Session 69
Lounge 9th Floor
THE PRIVATIZATION OF MEDICARE, ADVANTAGE OR NOT?
As the debate over Medicare’s future intensifies, oncology leaders are grappling with the potential impacts of increased privatization on cancer care delivery. The push towards expanding Medicare Advantage (MA) plans, championed by some policymakers, promises benefits like care coordination and supplemental services. However, it also raises concerns about access, administrative burdens, and financial toxicity for cancer patients. Recent studies have highlighted disparities in cancer treatment access between traditional Medicare and MA plans, with MA enrollees facing more limited provider networks and potential delays in receiving high-cost drugs. Further, the implementation of prior authorization requirements by MA plans has led to treatment delays and increased physician burnout. While MA plans offer potential cost savings and additional benefits, they also introduce complexities in coverage decisions and may limit patients’ choices of specialists and treatment centers. This panel will discuss the pros and cons of Medicare privatization and its impact on the quality and accessibility of cancer care for America’s seniors.
Moderator:
Chris Stewart, VP of Value & Access, Petauri
Faculty:
Lalan Wilfong, MD, CMO, Navista
Bryan Loy, MD, MBA, Consultant and former Corporate Medical Director
Todd Stevens, MBA, Chief Development Officer, OneOncology
Elizabeth Anderson, MBA, Senior Managing Director, Evercore ISI
Amy Alverson, MHA, Senior Director, Payer Relations & Strategy, The US Oncology Network

Key Opinion Leader Session 70
Presidents 10th Floor
SITE OF CARE: WHERE CANCER CARE IS DELIVERED TODAY AND WHERE IT’S HEADED TOMORROW
Is mandatory steerage to lower-cost settings a “redirection” or “rationing”? This panel examines the tension between NCI-designated centers and community clinics, and whether the “site-neutral” push is truly better for the patient or just the bottom line.
Moderator:
Deirdre Saulet, PhD, Advisor, New Rules Health Solutions
Faculty:
Ray Page, DO, PhD, FASCO, Senior Advisor and Director of Research, Center for Cancer and Blood Disorders
Connie Sullivan, CEO and President, NHIA
Nicolas Ferreyros, Managing Director, Community Oncology Alliance
Pete Scruggs, Founder & CEO, benefitSMART Cancer Solutions
Robert Daly, MD, MBA, Thoracic Oncologist, Memorial Sloan Kettering Cancer Center; Co-Founder, Greatly Health
Aaron Hannon, Co-Founder & CEO, Luminate

Key Opinion Leader Session 71
Olympic Suite 1 10th Floor
CLOSING THE CLINICAL TRIAL GAPS 
Discussion on the role of trials in cancer VBC, and components of trial enrollment that are necessary for better enrollment, and can be enabled through AI + technology
Audience: pharma, payers, patient advocates, community oncology, trial enrollment enablers.
Moderator:
Adam Boruchov, MD, SVP and Chair, The Cancer Institute Hartford Healthcare
Faculty:
Yousuf Zafar, MD, MHS, FASCO, Chief Medical Officer, AccessHope
Yale Podnos, MD, MPH, FACS, CMO, Starling Oncology
Davey Daniel, MD, Chief Medical Officer, OneOncology
Jennifer Carter, MD, MPH, MBA, Founder & CEO, Medzown
Susan Sabo-Wagner, MSN, RN, OCN, NEA-BC, VP of Clinical Innovation, AON
Mark Lee, MD, PhD, CEO, NPower Medicine

Key Opinion Leader Session 72
Olympic Suite 5 10th Floor
REALIZING CROSS-STAKEHOLDER VALUE: READOUT FROM THE INAUGURAL AVBCC SOUTHERN CALIFORNIA REGIONAL EVENT
Leadership Discussion:
Jon Zimmerman, Co-Chair, AVBCC Regional Collaborative
Harlan Levine, MD, President, Health Innovation and Policy, City of Hope
Kommah McDowell, MSLM, Patient, City of Hope

Key Opinion Leader Session 73
Lounge 9th Floor
PBM & DRUG REFORM’S IMPACT ON ONCOLOGY: WHO WINS, WHO LOSES, AND WHAT ACTUALLY CHANGES?
PBM reform is accelerating, but its real impact on community oncology remains uncertain. This panel will examine how proposed and enacted PBM reforms could change reimbursement, patient access, and the financial sustainability of communitybased care. Panelists will explore whether PBM reform meaningfully addresses the challenges facing oncology practices—or simply shifts cost and complexity elsewhere in the system. 
Moderator:
Michael Kolodziej, MD, CMO, Canopy
Faculty:
Joel White, Partner, Head of Health Practice, Monument Advocacy
Nicolas Ferreyros, Managing Director, Community Oncology Alliance
Ben Jones, SVP, Government Relations & Marketing, Oncology & Multispecialty, McKesson & The US Oncology Network
James Gilmore, PharmD, Chief Pharmacy & Procurement Officer, AON
Abby Finn Barnes, Director, Federal Government Relations, Cardinal Health
Blase Polite, MD, MPP, FACO, Professor of Medicine, University of Chicago; Physician-in-Chief, NWI

AVBCC Town Hall
Presidents 10th Floor
MEDICARE PART B EFFECTUATION: REPORT FROM AVBCC’S WORKING GROUP
The panel will discuss the work of the AVBCC Medicare Part B Effectuation Working Group, and its recommendations to CMS, as well as effectuation issues in Medicare Part D and any recent communications or actions from CMS across both programs. 
Moderator:
John Coster, PhD, RPh, Former Director, Division of Pharmacy, CMCS, CMS; Former Senior Technical Advisor, MDRNG, CM, CMS
Faculty:
Barbara McAneny, MD, Past President, American Medical Association; Co-Chair, ONCare Alliance; CEO, New Mexico Oncology Hematology Consultants
Rebecca Hancock, MHA, Senior Director, U.S. Policy & Strategy, Johnson & Johnson
Sean Hosp, VP, Policy Economics, Cencora
Katie Holcomb, FSA, MAAA, Principal and Consulting Actuary, Milliman
Kim Czubaruk, JD, VP of Policy, CancerCare
Weston Kirby, Director, Above Brand Strategy, US Oncology Care & Access, AstraZeneca

Key Opinion Leader Session 74
Olympic Suite 1 10th Floor
FROM DATASET TO DECISION: TURNING EVIDENCE INTO POLICY
Data alone rarely changes policy. This session examines how providers, advocacy organizations, and industry stakeholders can use real-world evidence and economic analyses to influence legislative and regulatory decisions.
Moderator:
Laura Housman, DrPH, MBA, MPH, Chief Public Health Officer, Avalere
Faculty:
Suzanne Belinson, PhD, VP, Commercial Markets, Tempus AI
Michelle Robb, FSA, MAAA, Senior Consulting Actuary, Milliman
Cleo Ryals, PhD, Sr. Director of Community Oncology Research Partnerships, Flatiron Health
Caitlin Sheetz, MPH, SVP and Head, Strategic Analytics, Value, and Economics, ADVI Health
Amy Eaves, VP, Real-World Evidence, Cardinal Health

Key Opinion Leader Session 75
Olympic Suite 5 10th Floor
DETECTING VALUE: THE FRAMEWORK FOR MEASURING CLINICAL UTILITY OF SCREENING PROGRAMS
Early detection of cancer has been the focus of major initiatives across societies, public outreach programs, payers, and regulators. However, the framework for assessing the effectiveness and clinical utility of primary-care screening programs is under-examined. Drawing on the procedures of the U.S. Preventive Services Task Force (USPSTF), this panel will examine the critical chain of evidence required to demonstrate that screening does more than detect disease– such as, is there an identifiable at-risk population? Does earlier detection change care or outcomes? How does early detection impact false positivity rates? Do intermediate or biomarker outcomes predict morbidity and mortality? What are the potential harms or unintended consequences of screening and treatment?
Experts in methods for detecting cancer, and in study methods required, will link these questions into an analytic framework and discuss the issues, complexities, and decision-making associated with screening programs via a case study on the topic of Colorectal Cancer. This case study will cover existing screening programs and technologies, the evolving evidence base on patient benefit, and the current reimbursement landscape. Panelists will discuss how payers, HTA bodies, clinicians, and policymakers use these frameworks and the role of real-world evidence, economic modeling, and longitudinal evidence synthesis to evaluate screening programs. Attendees will gain practical insights into a central question facing healthcare systems worldwide: how can we assess when cancer screening delivers sufficient clinical and economic value to warrant widespread adoption and reimbursement?
Moderator:
Norm Shore, CEO, Patient Discovery
Faculty:
Keith Kallmes, President, Nested Knowledge
Cate Lockhart, PharmD, PhD, Chief Science Officer, AMCP; Executive Director, BBCIC
Rebecca Miksad, MD, MMS, MPH, Chief Medical Officer, Color Health
Whitney Amyot, PhD, Managing Director, EY
Brian Decker, MBA, President & CEO, EMOL Health

Effectuation Part B Reception
Sponsored by Cencora

BREAKFAST
7:00am – 8:00am

AI Demo Showcase
Lounge 9th Floor
AI ON DISPLAY: TRANSFORMING ONCOLOGY
Artificial intelligence is rapidly reshaping the oncology landscape, offering new ways to improve efficiency, generate insights, support decision-making, and address challenges across the cancer care ecosystem. This fast-paced showcase will bring AI innovation to life through a series of 10-minute demonstrations from companies developing solutions for oncology.
Rather than traditional presentations, participating companies will take the audience directly inside their AI platforms, demonstrating real-world capabilities, applications, and potential impact. Attendees will gain a firsthand look at emerging technologies and practical AI solutions designed to support stakeholders across oncology—from providers and practices to payers, manufacturers, and patients.
Faculty:
Reena Duseja, MD, MS, Physician Executive, Oracle
Joshua Feazell, MPH, Enterprise AI Strategy & Partnerships, Infinitus Systems
Lavi Kwiatkowsky, Founder & CEO, Canopy
Matthew Ko, Founder, CEO, DeepScribe
Dan Caron, Founder & CEO, Health Universe
Srulik Dovorsky, Co-Founder & CEO, TailorMed
Eric Schultz, SageForce
Sorena Nadaf-Rahrov, MS, MMI, PhDc, President & CEO, Cancer Center Informatics Society
Alex Lukashevich, Chief AI Officer, Forte Group / Tina Liu, MPH, Chief Product Officer, Local Infusion

Key Opinion Leader Session 77
Presidents 10th Floor
BI-SPECIFICS: COME OF AGE WITH A NO MARGIN, NO MISSION REALITY 
To quote a legendary colleague in cancer care, this past Dec ’25 the Bi-Specifics outcomes data at ASH was amazing!  Financing is a problem in this sector because it is very expensive and clinical techniques for the “start-up” dosing of bispecifics (the first 6-8 weeks) are currently badly under-reimbursed by all payers. The oncology landscape of 2026 is dominated by therapies with binary outcomes: they either offer a potential cure or cause life-threatening systemic toxicity. For patients on CAR-T, Bi-specifics, or chronic TKI/IO combinations, there is no “off-ramp.” Discontinuing treatment due to unmanaged side effects isn’t just a clinical setback; it is often a terminal event. In this “no-fail” environment, the success of a half-million-dollar therapy depends entirely on the precision of monitoring between clinic visits. This session explores the operational and clinical shift required to manage these high-stakes therapies. We will discuss why traditional reactive triage is obsolete for drugs that can trigger cytokine release syndrome (CRS) or neurotoxicity in hours, and how AI-driven longitudinal monitoring is the only way to move these therapies safely into the community and outpatient settings. This panel will discuss the discourse between innovation and the last of proper access process and reimbursement as the reality facing physicians and patients today. The panel will explore the topic in hopes of making recommendations to payers on how to solve the mission access when the science has never been better. 
Moderator:
Barry Brooks, MD, MBA, Medical Director of GPO Services, McKesson Specialty Health
Faculty:
Dan Nardi, CEO, Reimagine Care
Mickael Seyman, US General Manager, Resilience
Fred Divers, MD, Chief Medical Officer, American Oncology Network
Chris Nuesch, VP, Charles River Associates
Ray Page, DO, PhD, FASCO, Senior Advisor and Director of Research, Center for Cancer and Blood Disorders

Key Opinion Leader Session 78
Olympic Suite 1 10th Floor
FACTORS FOR PATIENTS AND OTHER STAKEHOLDERS IN IDENTIFYING AND ACCESSING QUALITY CANCER CARE
A panel on the disconnect between high clinical ratings (CMS, U.S. News) and actual patient experience – this would be a critical conversation that the industry often avoids.
Moderator:
Alan Klein, MBA, Chief Growth and Strategy Officer, Patient Advocate Foundation
Faculty:
Shelley Fuld Nasso, MPP, CEO, Cancer Nation
Bryan Loy, MD, MBA, Consultant and former Corporate Medical Director
Douglas W. Blayney, MD, FASCO, Professor of Medicine (Oncology), Emeritus, Stanford Medicine, Stanford University School of Medicine
Sean Khozin, MD, MPH, CEO, CEO Roundtable on Cancer & Project Data Sphere; Former FDA Oncology Center of Excellence
Renuka Iyer, MD, SVP, CMO, NCCN
Angela Taber, MD, Medical Director, Daymark Health

Key Opinion Leader Session 79
Olympic Suite 5 10th Floor
AUTOMATED ADAPTIVE RADIATION THERAPY
Adaptive radiation therapy (ART) traditionally involved re-imaging and replanning a radiation treatment plan when a cancer patient’s anatomy changed during a course of treatment (either through weight loss, tumor shrinkage, or physiologic changes). This was high resource work that can now be completely automated and completed with a touch of a button with the patient still on the linear accelerator table. Should the value of automated ART be equivalent to manual ART? How often can ART be reasonably used during a radiation treatment course? Would automated ART exacerbate disparities in rural, less resourced areas?
Moderator:
Join Y. Luh, MD, FACP, FACR, FASTRO, Radiation Oncologist, Providence Health
Faculty:
Amar Rewari, MD, MBA, FASTRO, Chief of Radiation Oncology, Luminis Health
Anthony Paravati, MD, MBA, Executive Medical Director, Oncology Service Line, Chief of Radiation Oncology, Kettering Health
Erika Chin, PhD, DABR, Senior Medical/Clinical Science Liaison, Varian – A Siemens Healthineers Company

Key Opinion Leader Session 80
Lounge 9th Floor
340B DATA MODERNIZATION: CLAIMS SHARING, CONTRACT PHARMACY OVERSIGHT, TECHNOLOGY INNOVATION – AND WHAT ABOUT THE PATIENT?
A deep dive into modern tools aimed at bolstering 340B compliance, claims validation, and audit preparedness, assessing the risks and rewards of next-gen claims clearinghouse models. 
Moderator:
Katheryne Richardson, PharmD, Chief Strategy Officer, Second Sight Solutions
Faculty:
Alexandra Williams, MPH, Director, Strategy and Innovation, AbbVie
Ted Slafsky, MPP, Publisher and CEO, 340B Report
Mark Ogunsusi, JD, PharmD, Partner, K&L Gates LLP
William Sarraille, JD, Select Counsel, Rare Access Action Project (RAAP)
Sue Barnhart, BS, 340B ACE, CPhT, 340B Program Director, Keystone Health
Robert Popovian, PharmD, MS, Founder, Conquest Advisors

Key Opinion Leader Session 81
Presidents 10th Floor
FROM OCM TO EOM TO AI: CAN BETTER MEASUREMENT MAKE CANCER CARE VALUE-BASED?
For more than a decade, value-based cancer care has promised to reward better outcomes rather than higher volume. Yet cancer care still largely runs on familiar fee-for-service economics: expensive drugs, ASP-based payment, pathway debates, and quality measures that often lack clinical force. The Medicare Oncology Care Model showed the problem clearly: it produced modest reductions in episode payments, but no significant improvement in hospitalizations, emergency department visits, or quality, and it generated an estimated net loss to Medicare after enhanced services and performance payments. CMS then designed the Enhancing Oncology Model to be more patient-centered and data-forward, adding ePROs, health-related social-needs screening, equity plans, CEHRT, and CQI data use. This panel will ask whether the missing ingredient has been measurement itself. The central question is whether AI, EHR-derived measures, mCODE/USCDI+ Cancer, and digital quality measurement can move VBCC from claims-based cost control toward clinically meaningful improvement for patients. Learn what OCM actually taught us, why CMS EOM  may still not be enough, why measurement may be the “missing operating system” for VBCC and whether a new era of AI and digital oncology data can create a plausible V3 model and will AI-EHR and digital quality measures can make oncology performance measurable in ways that are clinically meaningful, auditable, and actionable for patients. VBCC has not failed because the aspiration was wrong; it has stalled because oncology has lacked a usable measurement system.  The question for 2026 is whether AI, ePROs, EHR-derived data, and oncology interoperability standards can finally make value measurable enough to change care for patients. 
Moderator:
Bruce Quinn, MD, PhD, MBA, Principal, Bruce Quinn Associates LLC
Faculty:
Ira Klein, MD, Vice President, Medical Affairs and Payer Relations, Tempus AI
Ron Kline, MD, Retired CMO, Quality Measurement and Value-based Incentives Group at CCSQ/CMS
Gabriel Brooks, MD, MPH, Associate Professor of Medicine, Dartmouth Cancer Center and Geisel School of Medicine
Alexandra Chong, PhD, EOM Team Lead, CMS Innovation Center

Key Opinion Leader Session 82
Olympic Suite 1 10th Floor
ORAL ONCOLOGY LAUNCH STRATEGY: DESIGNING ACCESS, DISTRIBUTION, AND ADOPTION IN COMMUNITY ONCOLOGY
The continued growth of oral oncology therapies is reshaping how community oncology practices evaluate, adopt, and operationalize treatment. Unlike infused therapies, oral agents place significant responsibility for prescribing, adherence support, financial navigation, and ongoing patient management into already resource-constrained practice settings. For emerging manufacturers, launch success increasingly depends on early alignment across contracting, distribution, manufacturing, and practice-level execution within the community oncology ecosystem.
This panel would explore how oral oncology therapies move through community oncology networks and where early commercialization decisions most often determine success or failure. Discussion topics would include contracting strategies and their impact on access and adoption; distribution design ranging from closed/OOLD models to open distribution networks; and the downstream effects these decisions have on practice workflow, patient access speed, and adherence support services.
The conversation would also address critical upstream considerations, including manufacturing readiness, packaging design for real-world use, hub services, patient and provider support resources, and the role of advisory boards in shaping community-aligned commercialization strategy.
Overall, the session would focus on when to engage stakeholders, who needs to be aligned early, and what infrastructure should be established prior to launch to support successful adoption in today’s value-driven oncology environment.
Moderator:
Rob Besse, Senior Vice President, Principal, Archbow Consulting
Faculty:
Kathy Oubre, MS, CEO, Pontchartrain Cancer Center
Jon Hustmyre, Director, National Corporate Accounts, Market Access Oncology, Corcept Therapeutics
Michael French, VP, Manufacturer Business Development, Oncology GPOs, McKesson
Jonas Congelli, Associate Executive Director, NCODA
Lisa Smith, RPh, SVP & President, Specialty Distribution and Solutions, Cencora
Benito Fernandez, MBA, Chief Commercial Officer, Onco360

Key Opinion Leader Session 83
Olympic Suite 5 10th Floor
FROM MOLECULAR INSIGHT TO PATIENT IMPACT: CASE STUDIES FOR IMPROVING PATIENT OUTCOMES WHERE MOST CANCER CARE HAPPENS
Most people with cancer in the United States receive their care in community settings, where even small delays in diagnosis, testing, interpretation, or follow-up can shape the entire patient journey. This session will highlight two efforts aimed at making molecular medicine more usable in the places where most patients are seen.
Dr. Juvianee Estrada-Veras will discuss return of results through his ongoing experiences with Murtha Cancer Center’s longitudinal cohorts, with an emphasis on how patients, clinicians, and care teams can be supported when molecular findings move from research into clinical context. James Thackeray will describe Lumea’s work in urology, where digital pathology and workflow redesign are being used to improve the path from biopsy to diagnosis, molecular testing, and treatment decision-making. Dr. Nathanael Fillmore will bring a national VA perspective through real-world immune checkpoint inhibitor outcomes research, including what large health systems can teach us about treatment benefit, patient heterogeneity, and the gap between clinical trials and routine care. Dr. Alexander Arrow will then discuss an emerging approach to counteract tissue insufficiency in community hospital biopsies, to allow more patients to be sequenced and therefore have access to precision medicine.
Together, these examples will explore a practical question for value-based cancer care: how can molecular information become not only more advanced, but also more timely, understandable, and useful for the 85% of patients cared for in the community?
Moderator:
Jerry S.H. Lee, PhD, Professor and Director of the Precision Health Network, Arizona State University
Faculty:
James Thackeray, MBA, CEO, LUMEA
Alexander K. Arrow, MD, CFA, CEO, Virchow Medical, Inc.
Nathanael R. Fillmore, PhD, Assistant Professor of Medicine, Harvard Medical School
Juvianee Estrada-Veras, MD, Head, Murtha Cancer Center Research Program, Genetics; Associate Professor of Surgery, Uniformed Services University

Key Opinion Leader Session 84
Lounge 9th Floor
PHYSICIAN DRUG DEPENDENCY/SUSTAINABILITY: “IS THE WRITING ON THE HILL?”
In medical oncology, practices have been underpaid for services provided ever since chemotherapy administration has moved from the hospital to the outpatient clinic and practice. Margin on drugs has been used to offset the underpayment on services.
Moderator:
Michael Kolodziej, MD, Chief Medical Officer, Canopy
Faculty:
Jeffrey Scott, MD, President & Chief Medical Officer, Integra Connect
Michael Sherman, MD, MBA, MS, Former CMO, Harvard Pilgrim Health Care and Point32Health; currently Principal, Sherman Healthcare Solutions
Barbara McAneny, MD, Past President, American Medical Association; Co-Chair, ONCare Alliance; CEO, New Mexico Oncology Hematology Consultants
Puneeth Indurlal, MD, MS, EVP, Strategic Operations & Enterprise Solutions, American Oncology Network
Christopher Windham, MD, MHCM, MPHM, FACS FSSO, Chief Operating Officer & Chief Clinical Officer, Outcomes Matter Innovations

Key Opinion Leader Session 85
Presidents 10th Floor
THE RADIATION “BLACK BOX”: WILL EPISODE-BASED PAYMENTS FINALLY ALIGN RAD-ONC WITH VALUE BASED CARE? 
Radiation oncology remains one of the most siloed and fee-for-service-heavy sectors in cancer care. While the medical oncology side has matured through OCM/EOM, rad-onc is just now facing the reality of the ROCR Act and bundled payments. This panel will tackle the friction between high-cost technical innovation (Proton, SBRT) and the payer’s drive for evidence-based “shorter is better” fractionation. We will also dive into the “PA Paradox”—whether automated prior authorization is a tool for guideline adherence or a barrier to timely, curative care.
Moderator:
Jennifer Nesbit, MS, BSN, RN, OCN, Director of Oncology Nursing
Faculty:
Join Y. Luh, MD, FACP, FACR, FASTRO, Radiation Oncologist, Providence Health
Simul Parikh, MD, Radiation Oncologist, West Cancer Center & Research Institute
Jordan Johnson, MSHA, MLS, Founder, Bridge Oncology
Frank Lexa, MD, MBA, FACR, President and Vice Chairman, Department of Radiology, University of Pittsburg
Ron Kline, MD, Retired CMO, Quality Measurement and Value-based Incentives Group at CCSQ/CMS

Key Opinion Leader Session 86
Olympic Suite 1 10th Floor
REDEFINING PERFORMANCE-BASED COMPENSATION: STRATEGIES FOR ALIGNING PHYSICIAN INCENTIVES WITH MODERN ONCOLOGY CARE DELIVERY
Our panel will explore innovative approaches that leading academic and community oncology programs are using to redesign physician and APP compensation models. These strategies are crafted to align with hospital/health system strategic priorities, foster high-quality care, broaden patient access, improve care coordination and service line integration, and maximize the non-clinical activities required by care teams. Through a combination of real-world examples and open discussion, panelists will present practical tactics for developing compensation models that supplement the next generation of oncology care, including the forthcoming wave of increased demand. Furthermore, they will examine common challenges encountered during implementation and offer valuable guidance on achieving sustainable, high-performing results in today’s increasingly complex oncology environment.
Moderator:
Tony Kouba, Partner, ECG Management Consultants
Faculty:
Daphne Haas-Kogan, MD, MBA, Chair of Radiation Oncology, Mass General Brigham Cancer Center
Sai Yendamuri, MD, MBA, FACS, Chief Strategy Officer, SVP Business Development and Outreach; President and CEO, RPCI Oncology PC; Professor and Chair, Department of Thoracic Surgery; Director, Thoracic Surgery Research Laboratory, Roswell Park Comprehensive Cancer Center
Stephen Petersen, MBA, Chief Financial Officer, Knight Cancer Group
Lisa Jordan, EML, Chief Administrative Officer, COH Medical Foundation; Vice President, COH National Medical Center

Key Opinion Leader Session 87
Olympic Suite 5 10th Floor
THE EVOLVING ROLE OF POPULATION HEALTH DECISION-MAKERS
As the provider channel navigates value-based care, advanced therapies, care coordination, and evolving practice economics, population health decision-makers (PHDMs) have assumed greater influence, broader responsibilities, and new communication paradigms with oncologists, payers, vendors and manufacturers alike: Changing Roles & Responsibilities: How have the roles & responsibilities of PHDMs evolved over the past 2-3 years and what emerging challenges that these stakeholders are experiencing? Data-Driven Decision-Making: What internal & external data sources are most utilized by PHDMs to inform decision-making and in what situations is manufacturer-provided data actually impactful? Manufacturer Engagement: How are PHDMs changing what they expect from manufacturer engagement, and where are manufacturers falling short or getting it right? Future-State: What do stakeholders anticipate the future holds for the responsibilities of PHDMs and how can the industry broadly best support them to drive informed decision-making?
Moderator:
Matthew Cunningham, Managing Partner, Dedham Group
Faculty:
Blair McCarthy, Assistant Vice President, Oncology Strategy, Tampa General Hospital
Alti Rahman, MHA, MBA, CSSBB, Chief Strategy & Innovation Officer, AON
Nancy Ruscio Bell, VP Head of Market Access, Celcuity
Steve Peskin, MD, MBA, MACP, Chief Population Health Officer, CytoSPAR